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Outstanding eﬀects on antithrombin activity of
modiﬁed TBA diastereomers containing an
optically pure acyclic nucleotide analogue†
M. Scuotto,‡ M. Persico,‡ M. Bucci, V. Vellecco, N. Borbone, E. Morelli, G. Oliviero,
E. Novellino, G. Piccialli, G. Cirino, M. Varra,* C. Fattorusso* and L. Mayol
Herein, we report optically pure modiﬁed acyclic nucleosides as ideal probes for aptamer modiﬁcation.
These new monomers oﬀer unique advantages in exploring the role played in thrombin inhibition by a
single residue modiﬁcation at key positions of the TBA structure.
Introduction
Aptamers are short, structured, single-stranded RNA or DNA
ligands characterized by high aﬃnity and specificity for their
target molecules. Aptamers can be considered as oligonucleo-
tide analogs of antibodies,1,2 but, unlike antibodies, they can
be chemically derivatized to extend their lifetimes and/or their
bioavailability3,4 and, particularly, to explore the molecular
basis of their biological properties.5,6 The thrombin binding
aptamer (TBA) is a 15-mer oligonucleotide (ON) which folds
into a typical chair-like G-quadruplex structure containing one
TGT and two TT loops (Fig. 1).7–9 It binds thrombin acting as
an anticoagulant agent.10
The investigation of the complex and intriguing molecular
bases of TBA–thrombin interactions has lasted now for more
than two decades.11–14 There is a certain amount of
knowledge4,8,9,11–15 on the fact that TBA loops are fundamental
for both G-quadruplex folding and thrombin interaction. In
TBA experimentally determined structures, either alone8,9 or
in complex with thrombin,11–14 the TT loops always preserved
the same conformation, having T4 and T13 stacked on the
underlying G quartet and T3 and T12 available for thrombin
interaction. In contrast, the TGT loop showed higher confor-
mational flexibility, especially concerning the T7 residue,
which is reported to interact with thrombin in some X-ray
complexes.11,12 Previous structure–activity relationship (SAR)
studies on TBA analogues containing an acyclic nucleotide,
performed by us16,17 and others,18,19 confirmed that some
loop residues, specifically T4, T13, G8, and T9, are crucial to
preserve the G-quadruplex folding typology, whereas the
others, T3, T12, and T7, are uniquely involved in thrombin
inhibition. Indeed, ONs modified at T3, T12, and T7 showed
significantly diﬀerent biological behaviours with respect to
TBA, not related to the stability of their G-quadruplex struc-
ture. We rationalized17 the SARs obtained by substituting a or
b (Fig. 2) at T3, T12, and T7, through enzyme-aptamer multiple
binding modes (Fig. 3). Disadvantageously, since the intro-
duced residues a or b presented a pro-chiral carbon (Fig. 2),
each obtained modified sequence existed as a mixture of two
diastereomers.
On this basis, the substitution of the identified key residues
with a rationally designed and optically pure acyclic nucleoside
analogue would allow the investigation of the molecular bases
of TBA–thrombin interaction. Here, we successfully approach
this issue by the substitution of T3 or T7 or T12 with each
pure stereoisomer of the acyclic nucleoside c (Fig. 2).
Fig. 1 Schematic representation of the NMR derived structure of TBA.
White and black rectangles indicate G bases in anti and syn confor-
mation, respectively. Loop residues not stacked on the G tetrads are
highlighted by red circles.
†Electronic supplementary information (ESI) available: Fig. S1–S3 and Tables S1
and S2. See DOI: 10.1039/c4ob00149d
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Results and discussion
Synthesis
We adopted the Horhota method20 to obtain the stereo-
selective synthesis of R and S enantiomers of the acyclic
nucleoside c (R-c and S-c in Scheme 1, Fig. 2 and Fig. 4). The R
or S stereochemistry was attained by ring opening of the enan-
tiomerically pure chiral epoxides 2 by reaction with the modi-
fied nucleobase 1 (Scheme 1). Each achieved molecule was
converted into the corresponding phosphoramidite building
block (5a,b) and incorporated into the TBA sequence to obtain
a pool of six ONs (Table 1).
Structural characterization
To probe whether the introduction of R or S acyclic nucleoside
c at TBA position 3, 12 or 7 aﬀected the overall G-quadruplex
topology formed in solution, we characterized all modified
TBAs by circular dichroism (CD) and CD melting experiments.
As expected, in PBS and K+ (90 mM KCl, 10 mM K2HPO4,
pH = 7.3) buﬀers, the modified sequences fold into G-quadru-
plexes having CD profiles (Fig. 5) and apparent melting temp-
eratures (Table 2 and Fig. S1 in ESI†) comparable to that of
TBA. Particularly, a stabilizing eﬀect on the G-quadruplex
structure (ΔT = 4–5 °C) was attained by replacing the T residue
Fig. 2 Acyclic nucleosides mimicking thymine residues. The pro-chiral
carbon of a and b is labelled with #.
Fig. 3 Schematic representation of the four possible orientations of
TBA with respect to thrombin assuming the same strand polarity of the
X-ray complex. White and black rectangles indicate G bases in anti and
syn conformation, respectively.
Scheme 1 Synthesis of monomers 5a,b. (i) 1 1.0 g (6.6 mmol), 2 (pure
enantiomer R or S) 0.490 g (6.6 mmol), potassium carbonate 0.152 g
(1.1 mmol), dry DMF (24 mL), 12–18 h, 80 °C, yields R-c 60% and S-c
45%; (ii) R-c or S-c 560 mg (2.5 mmol), 4,4’-dimethoxytritylchloride
850 mg (2.5 mmol), 4-dimethylaminopyridine 15 mg (0.12 mmol), pyri-
dine (20 mL), 2.0 h, r.t., yields 85%; (iii) 4a,b 859 mg, (1.6 mmol),
2-cyanoethyl diisopropylchlorophosphoramidite 536 µL (2.4 mmol),
DIPEA 1.7 mL (10 mmol), DCM (9 mL), 40 min, r.t., yields 90%.
Fig. 4 CD spectra of modiﬁed acyclic nucleosides (3.6 × 10−4 M in
CH3OH) R-c (positive spectrum) and S-c (negative spectrum).
Table 1 Modiﬁed sequences containing the c derivatives instead of a T
residue. The incorporation of R-c or S-c stereoisomer was speciﬁed sub-
stituting, at each position, the letter T of the unmodiﬁed sequence for
the letter R or S, respectively
ON Sequence
TBA GGTTGGTGTGGTTGG
TBA-R12 GGTTGGTGTGGR12TGG
TBA-R3 GGR3TGGTGTGGTTGG
TBA-R7 GGTTGGR7GTGGTTGG
TBA-S7 GGTTGGS7GTGGTTGG
TBA-S12 GGTTGGTGTGGS12TGG
TBA-S3 GGS3TGGTGTGGTTGG
Fig. 5 CD spectra of TBA and modiﬁed ONs in PBS (A) and K+ phos-
phate buﬀer (B).
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at positions 3 and 12 with the R stereoisomer of c or at posi-
tion 7 with both the R and S stereoisomers.
Fibrinogen assay
The new ONs were then evaluated for their ability to inhibit
fibrinogen hydrolysis by a fibrinogen clotting assay. The clot-
ting of fibrinogen induced by human α-thrombin was
measured spectrophotometrically at diﬀerent aptamer concen-
trations, following the increase in absorbance at 380 nm as a
function of time (Fig. 6 and 7, Table 3, Fig. S2 in ESI,† and
Experimental section).
At 20 nM concentration, TBA and TBA-R12 prolonged the
basal clotting time of 56 and 199 s, respectively (Fig. 6 and
Table 3).
Thus, TBA-R12 was 3.5 fold more active than TBA. At the
same concentration, TBA-S12 was completely inactive (Fig. 7
and Table 3). A similar activity trend was also observed
between TBA-R3 and TBA-S3, the former being 1.9 fold more
active than TBA, and the latter completely inactive (Fig. 6 and
7 and Table 3). These activity trends were maintained at all
tested concentrations, thus evidencing a stereoselective inter-
action with the target, involving the modified T12 or T3 resi-
dues, which is crucial for thrombin inhibition.
Molecular modelling studies
The resulting SARs of the new modified ONs were rationalized
with the aid of molecular modelling studies (see the Experi-
mental section for details). As observed by Feigon et al.8 and
confirmed by X-ray data,12,14 due to the TBA symmetry, resi-
dues T3 and T12 occupy equivalent positions with respect to
the G quartets and, by consequence, their binding clefts at
thrombin Exosite I (ABE I) can be “exchanged” by rotating the
structure 180° around the Y-axis (binding modes III and IV in
Fig. 3 and 8). Conversely, the TBA symmetry is lost when either
T3 or T12 is modified and, in particular, TT loops are no
longer equivalent. In our case, the monomer c is characterized
by (i) higher conformational flexibility and (ii) greater steric
hindrance with respect to thymidine. Our computational
results indicated that TBA-R3 and TBA-R12, which preserved
the stereochemistry of the thymidine residue, could easily
adopt bioactive conformation of the TT loops (Fig. 9a). The sig-
nificant increase in inhibitory activity of TBA-R3 and TBA-R12
with respect to TBA indicates the presence of additional
favourable hydrophobic contacts with the protein in, at least,
one of the TT loop binding clefts. In contrast, when the stereo-
chemistry of c is inverted with respect to the C-4′ carbon atom
of the natural counterpart (i.e., TBA-S3 and TBA-S12), it is not
possible for both binding sites and TT loops to properly place
at their thrombin whatever binding mode is assumed. Indeed,
Table 2 Tm values of TBA and modiﬁed ONs
ON
Tm °C (±1.0 °C)
K+ PBS
TBA 50 34
TBA-R12 55 39
TBA-R3 55 39
TBA-R7 54 38
TBA-S7 56 39
TBA-S12 51 35
TBA-S3 51 35
Fig. 6 Prolonged ﬁbrinogen clotting time (s) in the presence of TBA or
each active aptamer at diﬀerent concentrations (15–100 nM). The
graphics were drawn from scattering curve data.
Fig. 7 Prolonged ﬁbrinogen clotting time (s) in the presence of TBA,
TBA-S3, or TBA-S12 at diﬀerent concentrations (30–200 nM). The
graphics were drawn from scattering curve data.
Table 3 Prolonged ﬁbrinogen clotting times of TBA and modiﬁed ONs.
Each value was calculated subtracting the clotting time produced by
thrombin in the absence of any inhibitor (i.e., 25.6 ± 1.5 s) from that
measured in the presence of the aptamer
Prolonged clotting time (s)
ON 15 nM 20 nM 30 nM 100 nM 200 nM
TBA 24.6 ± 2.7 56.4 ± 5.0 159.4 ± 11.3 256.4 ± 19.7 N.T.a
TBA-R12 105.4 ± 5.7 198.9 ± 10.1 463.4 ± 13.6 759.6 ± 23.8 N.T.
TBA-R3 50.4 ± 4.0 108.4 ± 5.1 323.4 ± 12.5 576.4 ± 22.8 N.T.
TBA-R7 49.4 ± 3.0 89.4 ± 3.8 167.4 ± 6.0 304.4 ± 19.9 N.T.
TBA-S7 39.5 ± 3.0 67.4 ± 4.0 181.4 ± 9.7 355.4 ± 18.0 N.T.
TBA-S12 N.A.
b N.A. 10.9 ± 5.7 16.4 ± 2.8 24.4 ± 3.7
TBA-S3 N.A. N.A. 4.9 ± 3.0 18.4 ± 5.1 26.4 ± 4.6
aNot tested. bNot active.
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although monomers c are characterized by higher structural
flexibility with respect to thymine, TT loop conformation is
highly limited by the stacking of T4 and T13 on the G-quartet
(Table S1 in ESI†). Therefore, when the nucleobase analogue
moiety of c in TBA-S3 and TBA-S12 projects in the same direc-
tion as the nucleobase of T3 and T12 in the bioactive confor-
mation of TBA,11,12,14 the succeeding phosphate group (i.e., P4
or P13) is forced to distance itself from the G-quartet plane,
likely causing steric clashes with the protein backbone (Fig. 9b).
Another important outcome which emerged from our
results is the higher inhibitory activity of TBA-R12 compared
to TBA-R3.
In this case, the lack of structural symmetry does not
explain the diﬀerence in activities of TBA-R12 and TBA-R3,
since the same TT loop binding mode at thrombin ABE I could
be achieved for both analogues by rotating the structure by
180° (Fig. 8). This indicates that, although TT loops–ABE I
interaction is necessary for biological activity, it is not the only
factor able to modulate the inhibition of thrombin. Further
considerations can be done taking into account the results
obtained with aptamers modified at position 7 of the TGT
loop. The substitution of T7 with the R or S enantiomer of c
produced almost equally active aptamers (Fig. 2 and Table 3).
On the one hand, the lack of significant stereoselectivity of
action between the two diastereomers would suggest that the
TGT loop is not directly involved in thrombin binding. On the
other hand, TBA-R7 and TBA-S7 showed increased inhibitory
activity (either with respect to TBA and to previously developed
analogues bearing the monomer b)17 which cannot be
ascribed to the increased stability of the quadruplex structure
(Tm (PBS) TBA = TBA-T7b
17 = 37.5 °C; TBA-R7 = 38 °C; TBA-S7 =
39 °C), thus supporting the possible direct involvement of the
TGT loop in thrombin inhibition.11,12,17,18 Our molecular mod-
elling studies showed that, contrary to what was observed for
the more rigid TT loops, the higher conformational flexibility
of the TGT loop allows both c enantiomers to adopt the bio-
active conformation11,12 of the residue at position 7, without
aﬀecting the height of P7–P9 phosphate groups from the
underlying G tetrad plane (Fig. 10). In particular, most TBA-R7
conformers presented, similarly to TBA bioactive confor-
mation, G8 stacked on the G1–G6–G10–G15 quartet and T9
pointing outside (Fig. 10a and Table S1 in ESI†).
The opposite trend was observed for TBA-S7 (Fig. 10b and
Table S1 in ESI†). Analyzing our results in the light of reported
TBA–thrombin binding modes and X-ray structures,11–14 it
resulted that the two diﬀerent TGT loop conformations can
assume the binding modes I (Fig. S3a and S3c in ESI†) and II
(Fig. S3b and S3d in ESI†) represented in Fig. 3.
Taken together, our results indicate that both TT loops and
the TGT loop are involved in thrombin inhibition, but play
diﬀerent roles. The TT loops are necessary for high aﬃnity
thrombin inhibition by establishing a stereoselective inter-
action with the protein through residues at positions 3 and 12.
In contrast, the TGT loop seems to be involved in less specific
interactions with thrombin. Indeed, the TGT loop is not
suﬃcient for significant thrombin binding when the binding
ability of the TT loops is impaired (TBA-S3 and TBA-S12). More-
over, no significant stereoselectivity of action was observed
between TBA-R7 and TBA-S7. The results of our molecular
Fig. 8 X-ray structures of the complex between TBA and human
α-thrombin presenting aptamer TT loops interacting with thrombin ABE
I. (a) and (c) Binding mode III; PDB structure 1HAO (TBA carbons = cyan).
(b) and (d) Binding mode IV; PDB structure 4DIH (TBA carbons = yellow).
Heteroatoms are coloured as follows: O = red; N = blue; P = magenta.
Thrombin ABE I is shown as a green ribbon.
Fig. 9 (a) TBA-R12 (carbons = orange) and (b) TBA-S12 (carbons = pink)
superimposed on the bioactive conformation of TBA in complex with
thrombin (carbons = cyan; PDB ID: 1HAO). Heteroatoms are coloured as
follows: O = red; N = blue; P = magenta. Thrombin ABE I is shown as a
green ribbon. Hydrogens are omitted with the exception of those
present in the modiﬁed residue chiral carbon (R-c12 and S-c12) and
in TBA T12 C4’. The position of P13 is highlighted by a dashed circle and
an arrow.
Fig. 10 (a) TBA-R7 (carbons = orange) and (b) TBA-S7 (carbons = pink)
superimposed on the bioactive conformation of TBA in complex with
thrombin (carbons = green; PDB ID: 1HAP). Heteroatoms are coloured
as follows: O = red; N = blue; P = magenta. Thrombin ABE I is shown as
a green ribbon. Hydrogens are omitted with the exception of those
present in the modiﬁed residue chiral carbon (R-c12 and S-c12) and
in TBA T7 C4’.
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modelling studies suggest that the flexibility of the TGT loop,
together with the availability of multiple aptamer-protein
binding modes, likely contributes to the observed lack of
stereoselectivity between TBA-S7 and TBA-R7. Anyway, a single
modification of the TGT loop at position 7 can enhance throm-
bin inhibition, through a still undefined molecular mechan-
ism. A fascinating hypothesis, supported by some available
X-ray data,11,12 is that the high aﬃnity binding of the TT loops
could drive the interaction of the TGT loop with a second unit
of thrombin, and this, in turn, due to thrombin allostery,
somehow favours the binding of another TBA monomer in a
cooperative mechanism.
Experimental
Materials and methods
Chemicals and anhydrous solvents were purchased from
Fluka-Sigma-Aldrich. TLCs were run on Merck silica gel 60
F254 plates. Silica gel chromatography was performed using
Merck silica gel 60 (0.063–0.200 mm). The API 2000 (Applied
Biosystems) mass spectrometer was used to perform the ana-
lyses of the intermediates and the monomer. Melting points of
intermediates R-c and S-c were measured using a Buchi
Melting Point B-540. NMR experiments were recorded using
Varian Mercury Plus 400 MHz and Unity Inova 500 MHz spec-
trometers and processed using the Varian VNMR software
package. NMR spectra were calibrated using the solvents’
residual proton or carbon signals as internal standards.
31P-NMR spectra were calibrated using triphenylphosphine as
an external standard (δ −6 ppm). Reagents and phosphorami-
dites for DNA syntheses were purchased from Glenn Research.
ON syntheses were performed on a PerSeptive Biosystem Expe-
dite DNA synthesizer. HPLC analyses and purifications were
carried out using a JASCO PU-2089 Plus HPLC pump equipped
with a JASCO BS-997-01 UV detector. CD experiments were per-
formed on a JASCO 715 spectropolarimeter equipped with a
PTC-348 temperature controller. The fibrinogen assay was per-
formed using a JASCO 530 UV spectrophotometer equipped
with the PTC-348 temperature controller. [α]20D values for R-c
and S-c were determined using a JASCO P-2000 polarimeter.
Molecular modelling calculations were performed on SGI
Origin 200 8XR12000 and E4 Server Twin 2× Dual Xeon 5520,
equipped with two nodes. Each node was 2× Intel Xeon Quad-
Core E5520, 2.26 GHz, 36 GB RAM. The molecular modelling
graphics were carried out on SGI Octane 2 workstations.
MALDI-ToF measurements were performed using a Voyager
DE-STR instrument (Applied Biosystems). High resolution
mass spectra of 5a and 5b were performed on a Thermo LTQ
Orbitrap XL mass spectrometer (ESI positive mode).
Synthesis procedure
Synthesis of monomers 5a and 5b
6,7-Dihydro-1H-cyclopenta[d]pyrimidine-2,4(3H,5H)-dione
(1). 1 was obtained as previously reported by Takaya et al.21
Briefly, a solution of ethyl-2-oxocyclopentanecarboxylate (10 g,
64.0 mmol), urea (5.76 g, 96 mmol) and HCl (37% w/w,
0.096 mL) in EtOH (20 mL) was refluxed for 3 h. After fil-
tration, the collected white solid was suspended in 5% NaOH
(24 mL) and refluxed for 1 h. The reaction was cooled to room
temperature and the solid 1 collected by filtration and dried
(yields 60%; Rf 0.42 in 9 : 1 CH2Cl2–CH3OH, v/v).
1H (400 MHz, mixture of CD3OD and CDCl3): δ 4.00 (bs,
2H), 3.62 (m, 4H), 3.03 (t, J = 7.3 Hz, 2H), 2.67 (t, J = 7.3 Hz,
2H), 2.10 (q, J = 7.3 Hz, 2H).
13C (400 MHz, mixture of CD3OD and CDCl3): δ 166.3,
155.2, 147.3, 113.4, 34.8, 30.5, 18.0.
ESI mass (positive mode): calculated 152.1; found 153.1
[M + H]+, 175.1 [M + Na]+.
1-(2,3-Dihydroxypropyl)-6,7-dihydro-1H-cyclopenta[d]pyrimidine-
2,4(3H,5H)-dione [S-c or R-c].20 A mixture of compound 1 (1.0 g,
6.6 mmol) and anhydrous potassium carbonate (0.152 g,
1.1 mmol) in dry DMF (24 mL) was heated at 80 °C for 5 min.
Compound 2 (pure enantiomer R or S) (0.490 g, 6.6 mmol) was
then added. The reaction mixture was stirred at 80 °C for 18 h
under argon. The solution was concentrated under reduced
pressure and the residue purified by column chromatography
on silica gel eluted with 90 : 10 CH2Cl2–CH3OH to give S-c or
R-c as white solids (yields S-c 45%, R-c 60%, each of them
calculated as the average of two diﬀerent reactions). Fig. S1†
reports the CD profiles of each pure enantiomer S-c or R-c.
S-c 1H NMR (400 MHz, pyridine-d5): δ 4.66 (m, 1H, CHOH),
4.45 (dd, 1H, J1 = 14.0 Hz, J2 = 3.6 Hz, CHaHbOH), 4.08 (d, 2H,
J = 5.2 Hz, CH2N), 3.93 (dd, 1H, J1 = 14.0 Hz, J2 = 8.6 Hz
CHaHbOH), 3.17 (m, 1H, CHaHb), 2.83 (m, 1H, CHaHb), 2.69
(m, 2H, CH2), 1.82 (m, 2H) (Fig. S4†).
S-c 13C NMR (100 MHz, CD3OD): δ 163.0, 160.4, 153.2,
111.6, 69.4, 63.9, 32.6, 27.0, 21.0 (Fig. S5†).
ESI mass (positive mode): calculated 226.1; found 227.1
[M + H]+, 249.1 [M + Na]+. [α]20D = –51.4.
S-c in the crystalline state was obtained from CH3COCH3–
CH3OH (99 : 1, v : v). The measured melting point was in the
range 141–143 °C.
R-c 1H NMR (400 MHz, pyridine-d5): δ 4.66 (m, 1H, CHOH),
4.45 (dd, 1H, J1 = 14.0 Hz, J2 = 3.6 Hz, CHaHbOH), 4.08 (d, 2H,
J = 5.2 Hz, CH2N), 3.93 (dd, 1H, J1 = 14.0 Hz, J2 = 8.6 Hz
CHaHbOH), 3.17 (m, 1H, CHaHb), 2.83 (m, 1H, CHaHb), 2.69
(m, 2H, CH2), 1.82 (m, 2H) (Fig. S6†).
R-c 13C NMR (100 MHz, CD3OD) 163.0, 160.4, 153.2, 111.6,
69.4, 63.9, 32.6, 27.0, 21.0 (Fig. S7†).
ESI mass (positive mode): calculated 226.1; found 227.1
[M + H]+, 249.1 [M + Na]+. [α]20D = +54.3.
R-c in the crystalline state was obtained from CH3COCH3–
CH3OH (99 : 1, v : v). The measured melting point was in the
range 141–143 °C.
1-(2,4-Dioxo-3,4,6,7-tetrahydro-2H-cyclopenta[d]pyrimidin-
1(5H)-yl)-3-((3-methoxyphenyl)(4-methoxyphenyl)(phenyl)methoxy)-
propan-2-yl-P-2-cyanoethyl-N,N-cianopropylphosphonamidate 5a
and 5b. Compounds R-c or S-c (560 mg, 2.5 mmol), 4,4′-
dimethoxytrityl chloride (850 mg, 2.5 mmol) and 4-dimethyl-
aminopyridine (15.0 mg, 0.12 mmol) were dissolved in dry
pyridine (20 mL). The resulting solution was stirred at room
Organic & Biomolecular Chemistry Paper
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temperature under argon for 1.5 h. Dry methanol (200 μL) was
then added to quench the reaction. After 30 min under stirring
the solution was concentrated under reduced pressure and the
residue purified by column chromatography on silica gel
(eluted with 95 : 5 : 1 CH2Cl2–CH3OH–Et3N) to give mono-
dimethoxytritylated derivative 4a or 4b as a white foam (1.16 g,
85% yield from each c stereoisomer; Rf 0.7 eluted with
CH2Cl2–CH3OH 95 : 5 v/v). The solid (859 mg, 1.6 mmol) was
dried in a vacuum overnight before being dissolved in
anhydrous DCM (9 mL) and diisopropylethylamine (1.7 mL,
10 mmol) under argon. 536 μL of β-cyanoethyl diisopropyl-
chlorophosphoramidite was then added (2.4 mmol). After
40 min the reaction was quenched by addition of dry methanol
(100 μL), diluted with ethyl acetate (15 mL) and finally washed
with 10% sodium carbonate solution (15 mL) and brine
(15 mL). The organic layer was dried on magnesium sulphate
and concentrated in a vacuum. The residue was purified by
silica gel chromatography eluted with n-hexane, ethyl acetate,
and triethylamine (80 : 10 : 10). The fractions containing the
product were collected and concentrated under vacuum yield-
ing the phosphoramidite building block 5a [from R-c] or 5b
[from S-c] as a white foam (1.05 g, 90% Rf 0.75 in CHCl3–
MeOH–TEA 97 : 3 : 0.05 v/v). HPLC chromatograms (Fig. S14
and S15†) were used to confirm yields of the conversions of 4a
and 4b to 5a and 5b. After the washing procedure, the concen-
trated organic layers were dissolved in DCM and analyzed on a
Hypersil silica gel column, particle size 5 μm, eluted with
50 : 50 n-hexane–ethyl acetate. Rt: 5a 15.1 and 5b 14.7 [min].
The yields of reactions, calculated as the ratio between the area
of the peak produced by 5a or 5b and the total area of peaks,
were 92 and 89%, respectively.
1H NMR (500 MHz, DMSO-D6): δ 11.05 (1H), 7.41–7.24
(9H), 6.87 (4H), 4.18 (m, 1H), 3.93 (m, 1H), 3.78 (s, 6H),
3.78–3.40 (m, 3H), 3.14–2.85 (m, 3H), 2.65 (m, 1H), 2.49 (m,
4H), 1.92 (m, 2H), 1.08–0.97 (m, 12H) (Fig. S8 and S9†).
13C-NMR (100 MHz, DMSO-D6): δ 162.0, 159.0, 158.6, 153.0,
145.5, 136.2, 130.5, 128.7, 128.5, 127.5, 119.5, 114.0, 111.5,
86.4, 70,6, 65.2, 59,0, 55.9, 49.0, 43.3, 32.9, 28.0, 25.2–24.9,
21.2, 20.5 (Fig. S10 and S11†).
31P-NMR (202 MHz, DMSO): δ 148.9, 148.2 (Fig. S12 and
S13†).
HR-ESI mass (positive mode): calculated 728.3339; found
751.3216 [M + Na]+. Results of mass spectra are shown in
Fig. S16 and S17.†
5a [α]20D = +55.3 (solvent CH3CN); 5b [α]
20
D = –45.7 (solvent
CH3CN).
Synthesis of oligomers. TBA and analogues were syn-
thesized using standard solid phase DNA chemistry on a
controlled pore glass (CPG) support following the β-cyanoethyl
phosphoramidite method. The oligomers were detached from
the support and deprotected by treatment with an aqueous
ammonia solution (33%) at 55 °C overnight. The combined fil-
trates and washings were concentrated under reduced
pressure, dissolved in H2O, and purified by HPLC using an
anionic exchange column eluted with a linear gradient (from
0% to 100% B in 30 min) of phosphate buﬀer at pH 7.0 (A:
20 mM NaH2PO4 aqueous solution containing 20% CH3CN; B:
1.0 M NaCl, 20 mM NaH2PO4 aqueous solution containing
20% CH3CN, elution time 15.3 min). The oligomers were suc-
cessively desalted by molecular exclusion chromatography on
Biogel P-2 Fine. The purity was checked on HPLC using an
analytical reverse phase column (Purosphere RP-18, Merck).
Finally, the sequences were analyzed in negative mode by MAL-
DI-TOF experiments. Calculated molecular weight: [4710.25];
measured molecular weight: TBA-R3 [4710.72]; TBA-R7 [4710.94];
TBA-R12 [4710.54]; TBA-S3 [4710.11]; TBA-S7 [4711.57]; TBA-S12
[4710.72].
The concentrations of the samples used in CD and UV
experiments were determined by measuring the absorbance at
260 nm at 80 °C and using the open access program available
on http://basic.northwestern.edu/biotools/OligoCalc.html.22
CD experiments
To perform the CD experiments on modified nucleosides R-c
and S-c each compound was dissolved in CH3OH at the
final concentration of 3.6 × 10−4 M. The two solutions were
equilibrated for 10 min at r.t. and then the CD spectra were
registered.
To perform the CD experiments on modified TBA
sequences, each ON was dissolved in the potassium (90 mM
KCl, 10 mM KH2PO4, pH 7.4) or PBS (90 mM KCl, 10 mM
KH2PO4, pH 7.4) phosphate buﬀer at the final ON concen-
tration of 2.0 × 10−5 M and submitted to the annealing pro-
cedure (heating at 90 °C and slowly cooling at r.t.). Before each
experiment the samples were equilibrated at 10 °C for 30 min.
CD spectra were recorded from 200 to 400 nm at 100 nm
min−1 scanning rate, 16 s response, 1.0 nm bandwidth. Each
CD profile was obtained by taking the average of three scans
from which the spectrum of the background buﬀer was
subtracted.
CD melting–folding curves were obtained by monitoring
the variation of absorbance at 295 nm from 10 to 90 °C and
vice versa in K+ phosphate buﬀer (80 mM KCl, 20 mM KH2PO4
pH = 7.4) and PBS (147 mM NaCl, 20 mM NaH2PO4, 23 mM
KCl, pH = 7.4) at [ON] = 2.0 × 10−5 M using a 1.0 cm cuvette.
Two melting–folding experiments for each ON were recorded
at 0.5 °C min−1 and 1.0 °C min−1 heating–cooling rate. No sub-
stantial diﬀerences between melting and cooling curves were
detected. Both types of curves were independent of tempera-
ture scanning rate (0.5 °C min−1 or 1.0 °C min−1). Fig. S2†
shows the melting curves registered at the temperature
scanning rate of 1.0 °C min−1.
Fibrinogen clotting assay
The fibrinogen clotting times were measured spectrophoto-
metrically.23 ONs were incubated for 1 min at 37 °C in 1.0 mL
of PBS containing 2.0 mg mL−1 of fibrinogen (fibrinogen from
human plasma, F 3879, Sigma-Aldrich) in a PMMA cuvette
(vol. 1.5 mL, c.o. 1 cm, Brand). 100 μL of human thrombin
(10 NIH per mL; Sigma-Aldrich, T8885, human thrombin suit-
able for the thrombin time test) was then added to the solu-
tion containing the fibrinogen and the ON. The time required
Paper Organic & Biomolecular Chemistry
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for fibrin polymerization was determined from the UV scatter-
ing curve, registered as a function of time (wavelength fixed at
380 nm) in the presence of each ON. Each curve was deter-
mined in triplicate at diﬀerent concentrations. The clotting
time value reported as M ± SE was derived as the maximum of
the second derivative of each scattering curve. The basal clot-
ting time was determined by measuring the UV scattering as a
function of time produced in the absence of any ONs. The
15-mer GTGTGTGTGTTGTGT was used as the negative control.
In the absence of any inhibitor, the clotting time value was
25.6 ± 1.5 s. The prolonged fibrinogen clotting times of TBA
and modified ONs were calculated by subtracting the clotting
time produced by thrombin in the absence of any inhibitor
from that measured in the presence of the aptamer.
Molecular modelling
Experimentally determined structures of TBA alone (PDB ID:
148D) and in complex with thrombin (PDB IDs: 1HAO, 1HAP,
1HUT, 4DIH, and 4DII) were downloaded from the Protein
Data Bank (PDB, http://www.rcsb.org/pdb/) and analyzed using
the Homology module of Insight 2005 (Accelrys Software Inc.,
San Diego, CA). Hydrogens were added to all these structures
considering a pH value of 7.4 (Biopolymer Module, Insight
2005).
Since the replacement of T3, T7 and T12 residues with
nucleoside c produced diastereomers characterized by S or R
configuration at the acyclic linker, for each new TBA analogue,
the two diastereomers were built by modifying the experi-
mentally determined structure of TBA in complex with throm-
bin (PDB ID: 1HAO; Insight 2005 Builder module). Atomic
potentials and charges were assigned using the CVFF force
field.24
The conformational space of the new modified analogues
was sampled through 200 cycles of simulated annealing (SA)
followed by molecular mechanics (MM) energy minimization.
During the SA procedure, the temperature is altered in time
increments from an initial temperature to a final temperature
by adjusting the kinetic energy of the structure (by rescaling
the velocities of the atoms). The following protocol was
applied: the system was heated to 1000 K over 2000 fs (time
step of 1.0 fs); a temperature of 1000 K was applied to the
system for 2000 fs (time step of 1.0 fs) to surmount torsional
barriers; successively, the temperature was linearly reduced to
300 K in 1000 fs (time step of 1.0 fs). Resulting conformations
were then subjected to MM energy minimization within
Insight 2005 Discover_3 module (CVFF force field) until the
maximum rms derivative was less than 0.001 kcal Å−1, using a
conjugate gradient25 as the minimization algorithm. In order
to reproduce the physiological environment where these mole-
cules act and to evaluate the eﬀects of the implicit solvent, we
sampled the conformational space through the combined pro-
cedure of SA/MM calculations, using the dielectric constant of
water (ε = 80r). Moreover, in order to allow a complete relax-
ation of the structures preserving the monomolecular chair-
like G-quadruplex folding topology, during the entire course of
SA/MM calculations, we applied a tether force of 100 kcal Å−2
to the guanine bases of the two quartets.
Resulting conformers were analyzed and loop nucleotides
were classified on the basis of: (i) glycosidic bond χ values, i.e.,
0° < χ < 90° = syn; −60° < χ < −180° = anti;26 90° < χ < 180° and
−60° < χ < 0° = s/a; (ii) the interatomic distance between the
centroid of the ring atoms of the nucleobase of each loop
nucleotide and the centroid of the ring atoms of the nucleo-
bases of the two G-tetrads (Pseudo_Atom Define command,
Biopolymer Module, Insight 2005). When the distance was
<8 Å, the loop nucleotide was classified as “stacked”; when the
distance was >12 Å it was classified as “not-stacked”. A 3D
visual inspection was used to classify the nucleotide when the
distance was included between 8 Å and 12 Å. In any case, a
“stacked” nucleotide presented at least one nucleobase atom
under the G-tetrads. Occurrence rates were calculated for all
conformers (Tables S1 and S2 in ESI†).
New modified TBA conformers, resulting from SA/MM cal-
culations, were superimposed on the experimentally deter-
mined structures of TBA in complex with thrombin (PDB IDs:
1HAO, 1HAP, 1HUT, 4DIH and 4DII) by fitting heavy atoms of
the guanine bases of two quartets, and the overlap with the
residues interacting with thrombin ABE I was evaluated. All
possible TBA binding modes (Fig. 3) were considered. For each
aptamer/enzyme complex a subset around the ligand includ-
ing all protein and water molecules having at least one atom
within a 6 Å radius from any given aptamer atom was defined.
The created subsets were displayed and analyzed using Insight
2005 Biopolymer and Homology modules (Accelrys Software
Inc., San Diego, CA).
Conclusions
The results presented herein clearly establish the role of loop
conformational preferences on the overall TBA–thrombin com-
plexes and illustrate how a stereochemical modification can
impact on aptamer-protein recognition. Furthermore, since T
residues are often loop components of aptamers, our analyses
can be widely reproduced in other cases, using the R/S nucleo-
side derivatives c as two simple alternatives for the T residue,
to acquire and/or refine the structure–activity relationship
between aptamers and their targets.
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